Brought to you by 
Sciele Pharma gets rights to Addrenex's Clonicel
15 Jun 2012
Executive Summary
Start-up Addrenex Pharmaceuticals has licensed Sciele Pharma (prescription drugs for metabolic, cardio, gynecological, and pediatric diseases) exclusive North American marketing rights to Clonicel (clonidine), its Phase III candidate for hypertension and ADHD.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sciele Pharma gets rights to Addrenex's Clonicel
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice